CAS No.:85721-33-1

TOXICITY DATA with REFERENCE：

Organism	Test Type	Route	Reported Dose (Normalized Dose)	Effect	Source
man	LDLo	oral	5714ug/kg/2D- (5.714mg/kg)	BEHAVIORAL: COMA LIVER: "JAUNDICE, OTHER OR UNCLASSIFIED" LIVER: LIVER FUNCTION TESTS IMPAIRED	Lancet. Vol. 343, Pg. 738, 1994.
man	TDLo	oral	21mg/kg/3D-I (21mg/kg)	KIDNEY, URETER, AND BLADDER: URINE VOLUME DECREASED KIDNEY, URETER, AND BLADDER: PROTEINURIS KIDNEY, URETER, AND BLADDER: HEMATURIA	Annals of Pharmacotherpy. Vol. 29, Pg. 84, 1995.
man	TDLo	oral	21429ug/kg/3D (21.429mg/kg)	BEHAVIORAL: "HALLUCINATIONS, DISTORTED PERCEPTIONS" BEHAVIORAL: TOXIC PSYCHOSIS	Annals of Pharmacotherpy. Vol. 26, Pg. 930, 1992.
man	TDLo	oral	129mg/kg/6D-I (129mg/kg)	BEHAVIORAL: REGIDITY	Journal of Clinical Psychiatry. Vol. 54, Pg. 115, 1993.
man	TDLo	oral	200mg/kg (200mg/kg)	BEHAVIORAL: TREMOR GASTROINTESTINAL: NAUSEA OR VOMITING GASTROINTESTINAL: OTHER CHANGES	Annals of Pharmacotherpy. Vol. 28, Pg. 805, 1994.
mouse	LD50	intraperitoneal	1165mg/kg (1165mg/kg)		Ensho. Japanese Journal of Inflammation. Vol. 11, Pg. 343, 1991.
mouse	LD50	intravenous	122mg/kg (122mg/kg)	BEHAVIORAL: ALTERED SLEEP TIME (INCLUDING CHANGE IN RIGHTING REFLEX) BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY)	Korean Journal of Toxicology. Vol. 8, Pg. 161, 1993.
mouse	LD50	oral	5gm/kg (5000mg/kg)		Journal of Medicinal Chemistry. Vol. 33, Pg. 1344, 1990.
mouse	LD50	subcutaneous	> 1gm/kg (1000mg/kg)		Zhongguo Yaoxue Zazhi. Chinese Pharmacuetical Journal. Vol. 27, Pg. 297, 1992.
rat	LD50	intravenous	207mg/kg (207mg/kg)	BEHAVIORAL: ALTERED SLEEP TIME (INCLUDING CHANGE IN RIGHTING REFLEX) BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY)	Korean Journal of Toxicology. Vol. 8, Pg. 161, 1993.
rat	LD50	oral	> 2gm/kg (2000mg/kg)		Zhongguo Yaoxue Zazhi. Chinese Pharmacuetical Journal. Vol. 27, Pg. 297, 1992.
rat	LD50	subcutaneous	> 1gm/kg (1000mg/kg)		Zhongguo Yaoxue Zazhi. Chinese Pharmacuetical Journal. Vol. 27, Pg. 297, 1992.
women	TDLo	multiple routes	40mg/kg/6D-I (40mg/kg)	SKIN AND APPENDAGES (SKIN): "DERMATITIS, ALLERGIC: AFTER SYSTEMIC EXPOSURE" SKIN AND APPENDAGES (SKIN): "DERMATITIS, OTHER: AFTER SYSTEMIC EXPOSURE"	Acta Clinica Belgica. Vol. 49, Pg. 173, 1994.
women	TDLo	oral	10mg/kg (10mg/kg)	BEHAVIORAL: "HALLUCINATIONS, DISTORTED PERCEPTIONS" GASTROINTESTINAL: NAUSEA OR VOMITING	Allergy. Vol. 50(Suppl,
women	TDLo	oral	40mg/kg/2D-I (40mg/kg)	BEHAVIORAL: HEADACHE BLOOD: EOSINOPHILIA	American Journal of Medicine. Vol. 87, Pg. 589, 1989.
women	TDLo	oral	135mg/kg/3D-I (135mg/kg)	KIDNEY, URETER, AND BLADDER: "CHANGES IN TUBULES (INCLUDING ACUTE RENAL FAILURE, ACUTE TUBULAR NECROSIS)"	Archives of Internal Medicine. Vol. 153, Pg. 1258, 1993.
women	TDLo	oral	280mg/kg/2W-I (280mg/kg)	KIDNEY, URETER, AND BLADDER: "CHANGES IN TUBULES (INCLUDING ACUTE RENAL FAILURE, ACUTE TUBULAR NECROSIS)" KIDNEY, URETER, AND BLADDER: INTERSTITIAL NEPHRITIS SKIN AND APPENDAGES (SKIN): "DERMATITIS, ALLERGIC: AFTER SYSTEMIC EXPOSURE"	American Journal of Kidney Diseases. Vol. 22, Pg. 598, 1993.

Consensus Reports：

 

SAFETY PROFILE：

Safety Information of Ciprofloxacin (CAS NO.85721-33-1):
Hazard Codes: Xi
Risk Statements: 36/37/38
36/37/38:Irritating to eyes, respiratory system and skin  
Safety Statements: 26-36
26:In case of contact with eyes, rinse immediately with plenty of water and seek medical advice 
36:Wear suitable protective clothing  
WGK Germany: 2
RTECS: VB1993800

Standards and Recommendations：

 

Analytical Methods：